2003
DOI: 10.1001/archderm.139.3.273
|View full text |Cite
|
Sign up to set email alerts
|

Topical Imiquimod in the Treatment of Metastatic Melanoma to Skin

Abstract: An 86-year-old woman presented in 1999 with a malignant melanoma (Clark level IV; Breslow thickness, 1.9 mm) on her right knee, which was initially treated with wide excision. In August 2000, several skin lesions of metastatic melanoma were noted on the right lower leg. These were treated with carbon-dioxide laser ablation. Multiple new skin-colored, brownish red, and dark blue smooth-surfaced and eroded papules and nodules of metastatic melanoma appeared on the whole right lower leg in December 2000 (Figure 1… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
89
0
8

Year Published

2004
2004
2016
2016

Publication Types

Select...
5
4

Relationship

1
8

Authors

Journals

citations
Cited by 142 publications
(97 citation statements)
references
References 11 publications
0
89
0
8
Order By: Relevance
“…In addition, several controlled clinical trials as well as many smaller series of cases and case reports have demonstrated that imiquimod is also effective against a variety of primary skin cancers as well as cutaneous metastases of some malignancies. Cutaneous tumors that have responded well to topical treatment with imiquimod include basal cell carcinomas (Sterry et al, 2002;BathHextall et al, 2004;Geisse et al, 2004;Gollnick et al, 2005;Schulze et al, 2005), keratoacanthomas (Dendorfer et al, 2003;Peris et al, 2003), actinic keratoses (Stockfleth et al, 2001(Stockfleth et al, , 2002Lebwohl et al, 2004;Szeimies et al, 2004;Korman et al, 2005) and Bowen's disease (the latter two entities represent epidermal carcinoma in situ) (Patel et al, 2006;Peris et al, 2006), cutaneous metastases of melanoma (Steinmann et al, 2000;Bong et al, 2002;Ugurel et al, 2002;Wolf et al, 2003;Zeitouni et al, 2005), some cases of primary melanoma in situ (Fleming et al, 2004;Kamin et al, 2005;Ray et al, 2005;Wolf et al, 2005;Lonsdale-Eccles et al, 2006) and cutaneous T-cell lymphomas (Suchin et al, 2002;Dummer et al, 2003b;Chong et al, 2004;Deeths et al, 2005). Clinical responses of cutaneous neoplasias to topical treatment with imiquimod have also been observed in difficult-to-treat patient populations, such as organ transplant patients under immunosuppressive therapy (Smith et al, 2001;Prinz et al, 2004;Brown et al, 2005) or Xeroderma pigmentosum patients suffering from rapid development of multiple UV-induced cutaneous malignancies …”
Section: Antitumoral Efficacy Of Tlr7/8 Agonists In Clinical Trialsmentioning
confidence: 99%
“…In addition, several controlled clinical trials as well as many smaller series of cases and case reports have demonstrated that imiquimod is also effective against a variety of primary skin cancers as well as cutaneous metastases of some malignancies. Cutaneous tumors that have responded well to topical treatment with imiquimod include basal cell carcinomas (Sterry et al, 2002;BathHextall et al, 2004;Geisse et al, 2004;Gollnick et al, 2005;Schulze et al, 2005), keratoacanthomas (Dendorfer et al, 2003;Peris et al, 2003), actinic keratoses (Stockfleth et al, 2001(Stockfleth et al, , 2002Lebwohl et al, 2004;Szeimies et al, 2004;Korman et al, 2005) and Bowen's disease (the latter two entities represent epidermal carcinoma in situ) (Patel et al, 2006;Peris et al, 2006), cutaneous metastases of melanoma (Steinmann et al, 2000;Bong et al, 2002;Ugurel et al, 2002;Wolf et al, 2003;Zeitouni et al, 2005), some cases of primary melanoma in situ (Fleming et al, 2004;Kamin et al, 2005;Ray et al, 2005;Wolf et al, 2005;Lonsdale-Eccles et al, 2006) and cutaneous T-cell lymphomas (Suchin et al, 2002;Dummer et al, 2003b;Chong et al, 2004;Deeths et al, 2005). Clinical responses of cutaneous neoplasias to topical treatment with imiquimod have also been observed in difficult-to-treat patient populations, such as organ transplant patients under immunosuppressive therapy (Smith et al, 2001;Prinz et al, 2004;Brown et al, 2005) or Xeroderma pigmentosum patients suffering from rapid development of multiple UV-induced cutaneous malignancies …”
Section: Antitumoral Efficacy Of Tlr7/8 Agonists In Clinical Trialsmentioning
confidence: 99%
“…Topical imiquimod has also been used in a variety of different skin disorders including nodular and superficial BCC (29), in situ and invasive SCC (30)(31), lentigo maligna (32), lentigo maligna melanoma (33), keratoacanthomas (34), primary cutaneous CD30 positive anaplastic large cell lymphoma (35), mycosis fungoides (36), extramammary Paget's disease (37), cutaneous melanoma metastases (38), cutaneous warts and molluscum contagiosum (39), stucco keratosis (40), cutaneous leishmaniasis (41) and keloids (42).…”
Section: Imiquimod: a Promising Topical Immunostimulatory Agent For Dmentioning
confidence: 99%
“…2 O IM creme a 5% possui potente atividade antiviral e antitumoral e tem sido relatado como efetivo no tratamento de LM, 3,4,5 prevenindo a progressão para Lentigo Maligno Melanoma e uma opção no tratamento de metástases cutâneas de melanoma. 6,7,8 O tratamento correntemente recomendado para melanoma maligno in situ inclui excisão cirúrgica com margem mínima de 0,5cm. Esse tratamento pode não ser indicado em determinados casos (idade do paciente, tamanho e localização das lesões).…”
Section: Discussionunclassified